BICYCLE THERAPEUTICS PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23.41 USD | +3.58% |
|
+15.09% | +29.48% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 168.8 | 382.4 | 1,790 | 878.8 | 767 | 1,556 | - | - |
| Enterprise Value (EV) 1 | 76.71 | 260.9 | 1,381 | 570 | 280.6 | 1,238 | 1,302 | 1,466 |
| P/E ratio | -3.4 x | -6.75 x | -22.8 x | -7.79 x | -3.56 x | -5.23 x | -4.57 x | -4.48 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 12.2 x | 36.8 x | 153 x | 60.8 x | 28.4 x | 40.1 x | 49.4 x | 32.7 x |
| EV / Revenue | 5.56 x | 25.1 x | 118 x | 39.4 x | 10.4 x | 31.9 x | 41.3 x | 30.8 x |
| EV / EBITDA | -3.03 x | -5.15 x | -21.5 x | -5.05 x | -1.53 x | -6.43 x | -5.53 x | -5.26 x |
| EV / FCF | -2.54 x | -13.7 x | -82.1 x | -5.42 x | -4.42 x | -6.86 x | -5.69 x | -6.27 x |
| FCF Yield | -39.3% | -7.28% | -1.22% | -18.4% | -22.6% | -14.6% | -17.6% | -16% |
| Price to Book | - | - | 4.41 x | 3.24 x | 2.07 x | 3.15 x | 8.16 x | 33.4 x |
| Nbr of stocks (in thousands) | 17,903 | 21,305 | 29,400 | 29,689 | 42,422 | 68,856 | - | - |
| Reference price 2 | 9.430 | 17.95 | 60.87 | 29.60 | 18.08 | 23.41 | 23.41 | 23.41 |
| Announcement Date | 3/10/20 | 3/11/21 | 3/1/22 | 2/28/23 | 2/20/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 13.8 | 10.39 | 11.7 | 14.46 | 26.98 | 38.81 | 31.51 | 47.61 |
| EBITDA 1 | -25.34 | -50.68 | -64.21 | -113 | -183.4 | -192.4 | -235.6 | -278.9 |
| EBIT 1 | -26.3 | -51.96 | -65.62 | -116.7 | -189.9 | -208.4 | -249.5 | -269.5 |
| Operating Margin | -190.56% | -500.1% | -560.98% | -806.56% | -704.13% | -537.08% | -791.85% | -566.07% |
| Earnings before Tax (EBT) 1 | -30.86 | -51.73 | -68.48 | -114.2 | -179.2 | -201 | -244.5 | -260.1 |
| Net income 1 | -30.61 | -51.01 | -66.82 | -112.7 | -180.7 | -192.3 | -233.6 | -254 |
| Net margin | -221.78% | -490.95% | -571.25% | -779.35% | -669.72% | -495.45% | -741.13% | -533.57% |
| EPS 2 | -2.770 | -2.660 | -2.670 | -3.800 | -5.080 | -4.476 | -5.118 | -5.222 |
| Free Cash Flow 1 | -30.17 | -18.99 | -16.82 | -105.1 | -63.56 | -180.5 | -228.7 | -233.8 |
| FCF margin | -218.59% | -182.76% | -143.83% | -726.67% | -235.61% | -465.1% | -725.73% | -491.13% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/10/20 | 3/11/21 | 3/1/22 | 2/28/23 | 2/20/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 3.771 | 3.86 | 4.378 | 3.04 | 3.185 | 4.896 | 11.4 | 5.352 | 5.331 | 19.53 | 6.282 | 6.177 | 6.905 | 6.532 | 7.089 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -18.02 | -27.38 | -27.3 | -29.76 | -32.21 | -41.8 | -43.11 | -50.8 | -54.24 | -31.72 | -53.25 | -58.38 | -66.04 | -59.46 | -61.21 |
| Operating Margin | -477.94% | -709.4% | -623.57% | -978.91% | -1,011.33% | -853.82% | -378.27% | -949.12% | -1,017.35% | -162.4% | -847.62% | -944.98% | -956.49% | -910.18% | -863.47% |
| Earnings before Tax (EBT) 1 | -18.78 | -27.98 | -27.28 | -28.58 | -30.4 | -39.68 | -43.12 | -47.63 | -48.78 | -26.91 | -51.31 | -57.8 | -64.09 | -58.58 | -59.79 |
| Net income 1 | -18.04 | -27.56 | -26.83 | -28.35 | -29.98 | -39.06 | -42.6 | -49.9 | -49.1 | -26.56 | -49.07 | -55.22 | -60.75 | -58.58 | -59.79 |
| Net margin | -478.31% | -714.09% | -612.79% | -932.47% | -941.22% | -797.88% | -373.81% | -932.32% | -921.01% | -136.01% | -781.04% | -893.97% | -879.85% | -896.75% | -843.44% |
| EPS 2 | -0.6300 | -0.9300 | -0.9000 | -0.9600 | -1.010 | -1.300 | -1.410 | -1.260 | -1.160 | -0.6200 | -1.147 | -1.287 | -1.408 | -1.353 | -1.367 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/1/22 | 5/5/22 | 8/4/22 | 11/3/22 | 2/28/23 | 5/4/23 | 8/3/23 | 11/2/23 | 2/20/24 | 5/2/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 92.1 | 121 | 409 | 309 | 486 | 318 | 254 | 90.2 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -30.2 | -19 | -16.8 | -105 | -63.6 | -181 | -229 | -234 |
| ROE (net income / shareholders' equity) | - | - | -30.3% | -36.5% | -56.3% | -52.4% | -101% | -310% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | - | - | 13.80 | 9.130 | 8.740 | 7.420 | 2.870 | 0.7000 |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 1.56 | 1.2 | 2.03 | 19 | 2.93 | 3.67 | 3.37 | 4.73 |
| Capex / Sales | 11.27% | 11.55% | 17.35% | 131.28% | 10.86% | 9.45% | 10.68% | 9.94% |
| Announcement Date | 3/10/20 | 3/11/21 | 3/1/22 | 2/28/23 | 2/20/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
23.41
USD
Average target price
41.33
USD
Spread / Average Target
+76.56%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +29.48% | 1.56B | |
| +20.17% | 127B | |
| +24.67% | 117B | |
| +25.44% | 27.67B | |
| -17.74% | 20.33B | |
| -15.17% | 16.79B | |
| -15.21% | 15.63B | |
| +11.91% | 14.84B | |
| -47.10% | 14.65B | |
| +54.50% | 14.43B |
- Stock Market
- Equities
- BCYC Stock
- Financials Bicycle Therapeutics plc
